A joint development project by University of Helsinki and University of Turku, TEHO adaptive clinical trial design, has been awarded with over 2 million Euros in the Challenge Finland competition.
The goal of the 2-year project is to develop a new, faster and more efficient adaptive approach to clinical trials which constitute one major bottleneck in transforming Finnish innovations in cancer research into new, effective therapeutics.
The TEHO project includes the development and validation of a new multifaceted approach that utilizes latest data from preclinical cancer models, predictive biomarkers and computational simulations parallel to an active clinical trial. This way, the clinical significance of the proposed markers of clinical efficacy before and during the actual clinical testing. The new paradigm aims at dramatically decreasing the time and cost of clinical testing, thus accelerating clinical adoption of new cancer therapeutics.
TEHO is a collaborative partnership between academia and industry, whose members include University of Helsinki, University of Turku, Comprehensive Cancer Center, AbbVie Oy, Aurexel Life Sciences Ltd, Bayer Oy, Biomedicum Genomics Oy, Orion Oyj, PacoMed Oy and StatFinn Oy. Responsible project directors are the cancer scientists Juha Klefström from the University of Helsinki and Jukka Westermarck from the University of Turku.
Read more from the University of Helsinki web site